UCB SA (UCB.BR) Stock Fundamental Analysis

EBR:UCB • BE0003739530

285.4 EUR
+1.9 (+0.67%)
Last: Feb 18, 2026, 05:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to UCB. UCB was compared to 52 industry peers in the Pharmaceuticals industry. UCB is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. UCB is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes UCB very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year UCB was profitable.
  • UCB had a positive operating cash flow in the past year.
  • In the past 5 years UCB has always been profitable.
  • Each year in the past 5 years UCB had a positive operating cash flow.
UCB.BR Yearly Net Income VS EBIT VS OCF VS FCFUCB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • The Return On Assets of UCB (7.75%) is comparable to the rest of the industry.
  • The Return On Equity of UCB (13.76%) is comparable to the rest of the industry.
  • UCB has a Return On Invested Capital (11.63%) which is in line with its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 14.45%.
  • The 3 year average ROIC (4.35%) for UCB is below the current ROIC(11.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UCB.BR Yearly ROA, ROE, ROICUCB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • With a decent Profit Margin value of 19.45%, UCB is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • UCB's Profit Margin has been stable in the last couple of years.
  • The Operating Margin of UCB (26.58%) is better than 63.46% of its industry peers.
  • UCB's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 73.38%, UCB is in the better half of the industry, outperforming 63.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UCB.BR Yearly Profit, Operating, Gross MarginsUCB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • UCB has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, UCB has more shares outstanding
  • Compared to 1 year ago, UCB has an improved debt to assets ratio.
UCB.BR Yearly Shares OutstandingUCB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UCB.BR Yearly Total Debt VS Total AssetsUCB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • UCB has an Altman-Z score of 5.85. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
  • UCB's Altman-Z score of 5.85 is amongst the best of the industry. UCB outperforms 80.77% of its industry peers.
  • UCB has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as UCB would need 2.43 years to pay back of all of its debts.
  • UCB has a better Debt to FCF ratio (2.43) than 80.77% of its industry peers.
  • UCB has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • UCB has a Debt to Equity ratio of 0.29. This is in the better half of the industry: UCB outperforms 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.85
ROIC/WACC1.48
WACC7.88%
UCB.BR Yearly LT Debt VS Equity VS FCFUCB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 1.35 indicates that UCB should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.35, UCB is in line with its industry, outperforming 55.77% of the companies in the same industry.
  • UCB has a Quick Ratio of 1.01. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.01, UCB is in line with its industry, outperforming 53.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UCB.BR Yearly Current Assets VS Current LiabilitesUCB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.41% over the past year.
  • UCB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.86% yearly.
  • Looking at the last year, UCB shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
  • Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.00% on average over the next years. This is a very strong growth
  • UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.34% yearly.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
UCB.BR Yearly Revenue VS EstimatesUCB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UCB.BR Yearly EPS VS EstimatesUCB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 44.45, the valuation of UCB can be described as expensive.
  • UCB's Price/Earnings ratio is a bit more expensive when compared to the industry. UCB is more expensive than 65.38% of the companies in the same industry.
  • UCB is valuated expensively when we compare the Price/Earnings ratio to 27.16, which is the current average of the S&P500 Index.
  • UCB is valuated quite expensively with a Price/Forward Earnings ratio of 27.75.
  • The rest of the industry has a similar Price/Forward Earnings ratio as UCB.
  • UCB is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 44.45
Fwd PE 27.75
UCB.BR Price Earnings VS Forward Price EarningsUCB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 63.46% of the companies in the same industry are cheaper than UCB, based on the Enterprise Value to EBITDA ratio.
  • UCB's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 46.85
EV/EBITDA 22.64
UCB.BR Per share dataUCB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of UCB may justify a higher PE ratio.
  • A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.74
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.36%, UCB is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.91, UCB is paying slightly less dividend.
  • Compared to an average S&P500 Dividend Yield of 1.82, UCB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.36%

5.2 History

  • The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
UCB.BR Yearly Dividends per shareUCB.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 19.82% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
  • UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UCB.BR Yearly Income VS Free CF VS DividendUCB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UCB.BR Dividend Payout.UCB.BR Dividend Payout, showing the Payout Ratio.UCB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

EBR:UCB (2/18/2026, 5:36:15 PM)

285.4

+1.9 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)02-26
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap55.51B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts73.85
Price Target275.68 (-3.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.36%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.12%
PT rev (3m)9.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.55%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE 44.45
Fwd PE 27.75
P/S 8.11
P/FCF 46.85
P/OCF 35.22
P/B 5.73
P/tB 51.07
EV/EBITDA 22.64
EPS(TTM)6.42
EY2.25%
EPS(NY)10.28
Fwd EY3.6%
FCF(TTM)6.09
FCFY2.13%
OCF(TTM)8.1
OCFY2.84%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.74
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.85
F-Score9
WACC7.88%
ROIC/WACC1.48
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.34%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y41.09%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UCB.BR FAQ

What is the fundamental rating for UCB stock?

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.


Can you provide the valuation status for UCB SA?

ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.


Can you provide the profitability details for UCB SA?

UCB SA (UCB.BR) has a profitability rating of 6 / 10.


What are the PE and PB ratios of UCB SA (UCB.BR) stock?

The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 44.45 and the Price/Book (PB) ratio is 5.73.


What is the earnings growth outlook for UCB SA?

The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.